Last edition
News about "Mirabegron Patent Dispute"
Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement
Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.
Mirabegron Patent Dispute | 11/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy